Larimar Submits First Module Of BLA For Nomlabofusp, Reports Positive Long-Term FA Data

Larimar Therapeutics submitted the first module of a rolling BLA to the FDA seeking accelerated approval for nomlabofusp in Friedreich's ataxia. The filing advances its lead program through a key regulatory step and could support value creation if the application progresses smoothly. The update is positive for the stock, though it is only an initial submission and not yet an approval.

Analysis

Larimar Therapeutics submitted the first module of a rolling BLA to the FDA seeking accelerated approval for nomlabofusp in Friedreich's ataxia. The filing advances its lead program through a key regulatory step and could support value creation if the application progresses smoothly. The update is positive for the stock, though it is only an initial submission and not yet an approval.